Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD): Where Are We Now And Where Are We Going?Funders.

Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD): Where Are We Now And Where Are We Going?Funders. Curr Clin Pharmacol. 2020 Mar 11;: Authors: Naseer M, Poola S, Ali S, Samiullah S, Tahan V Abstract The incidence, prevalence, and cost of care associated with diagnosis and management of inflammatory bowel disease are on the rise. The role of gut microbiota in the causation of Crohn's disease and ulcerative colitis has not been established yet. Nevertheless, several animal models and human studies point towards the association. Targeting intestinal dysbiosis for the remission induction, maintenance, and relapse prevention is an attractive treatment approach with minimal adverse effects. However, the data is still conflicting. The purpose of this article is to provide the most comprehensive and updated review on the utility of prebiotics and probiotics in the management of active Crohn's disease and ulcerative colitis/pouchitis and their role in the remission induction, maintenance, and relapse prevention. A thorough literature was performed on PubMed, Ovid Medline, and EMBASE using the terms "prebiotics and ulcerative colitis", "probiotics and ulcerative colitis", "prebiotics and Crohn's disease", "probiotics and Crohn's disease", "probiotics and acute pouchitis", "probiotics and chronic pouchitis" and "prebiotics and pouchitis". Observational studies and clinical trials conducted on humans and published in the English lan...
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research